Through a rigorous selection process, CCAB has developed a portfolio of monoclonal research-grade reagent antibodies against an array of human targets involved in various diseases such as cancer and autoimmune disorders, highlighting the antibodies’ therapeutic value. The antibodies exhibit competitive properties for reagent use primarily by Flow Cytometry and ELISA applications. Read our recent blog to learn about the antibody reagent market.
How to order:
CCAB is partnering with MédiMabs Antibodies for global distribution of our antibodies. For researchers based in Toronto, contact MedStore at the University of Toronto. Order information is available in the tables below.
What CCAB offers:
- A robust portfolio of monoclonal antibodies (mAbs) against an array of human cell surface proteins
- Synthetic antibodies in different modalities and formats given the recombinant nature of our technology
- High specificity and sensitivity of antibody binding to its relevant target
- A robust set of validated antibodies using Flow Cytometry & ELISA
- Isoform-specific mAbs that allow profiling of proteins within a single receptor tyrosine kinase (RTK) family
Human Recombinant Antibody Portfolio
Our Specialty: Comprehensive sets of protein family profilers
- Isoform-specific antibodies within a receptor protein family
- Allows researchers to profile a family of RTK proteins
*FC = Flow Cytometry
*IF = Immunofluorescence
Into the reagent market – CCAB breaks into the reagent market with unique, reliable antibodies
Angiogenesis in cancer – Role of CD105 (endoglin)
Cell adhesion molecule CD146 and skin cancer – CD146 has been considered over the past years as a promising target for cancer immunotherapy
A receptor for cellular infiltration – CD44 role in T cell extravasation to inflammation site and cancer metastatic potential
TLR4 20 years later – Role in immunity and tumour progression
Which FGFR isoform drives cancer? – The promise of FGFR inhibitors in the clinic, but which FGFR isoform drives cancer?
Relevance of the FGFR isoforms profile in cancer – The comparison of the expression level of the different isoforms in genomic have shown to be a useful tool in research.
Custom companion diagnostic – Evaluating HER2 overexpression
For inquiries, please contact reagents@ccabcanadacom.